Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Miromatrix Medical Inc. MIRO
$1.12
На 18:04, 12 мая 2023
+703.57%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
34041625.00000000
-
week52high
4.95
-
week52low
1.11
-
Revenue
953470
-
P/E TTM
0
-
Beta
0.00000000
-
EPS
-1.41000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 20:00
Описание компании
Miromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. Its proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. The company has collaborations with The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Craig-Hallum | Buy | 19 июл 2021 г. | |
| Piper Sandler | Overweight | 31 авг 2022 г. | |
| Piper Sandler | Overweight | Overweight | 15 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Douglas James Michael | A | 40000 | 40000 | 13 янв 2023 г. |
| Douglas James Michael | A | 20000 | 20000 | 13 янв 2023 г. |
| Barry John Joseph | A | 20000 | 20000 | 13 янв 2023 г. |
| Barry John Joseph | A | 29235 | 10000 | 13 янв 2023 г. |
| Ross Jeffrey James | A | 100000 | 100000 | 13 янв 2023 г. |
| Ross Jeffrey James | D | 365026 | 4487 | 13 янв 2023 г. |
| Ross Jeffrey James | A | 369513 | 50000 | 13 янв 2023 г. |
| Ross Jeffrey James | D | 0 | 37500 | 06 дек 2022 г. |
| Ross Jeffrey James | D | 319513 | 11575 | 06 дек 2022 г. |
| Ross Jeffrey James | A | 331088 | 37500 | 06 дек 2022 г. |
Новостная лента
Miromatrix's stock is down 33%
Market Watch
15 дек 2022 г. в 08:35
Shares of Miromatrix Medical Inc. were down about 33% in premarket trading on Thursday, the day after the company said there's a clinical hold on its experimental acute liver failure treatment. Miromatrix had submitted the investigational new drug application for the therapy to the Food and Drug Administration last month.
Miromatrix Medical Inc. (MIRO) Q3 2022 Earnings Call Transcript
Seeking Alpha
15 ноя 2022 г. в 16:17
Miromatrix Medical Inc. (NASDAQ:MIRO ) Q3 2022 Results Conference Call November 14, 2022 4:30 PM ET Company Participants Hannah Jeffrey - IR Jeff Ross - CEO Jim Douglas - CFO Operator Greetings, and welcome to the Miromatrix Medical Inc.'s Third Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Miromatrix to Report Third Quarter 2022 Financial Results
GlobeNewsWire
03 ноя 2022 г. в 16:01
EDEN PRAIRIE, Minn., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will report financial results for the third quarter 2022 after market close on Monday, November 14, 2022. Company management will host a corresponding conference call beginning at 3:30 pm Central Time / 4:30 pm Eastern Time.
Miromatrix CEO Jeff Ross to Present at the 2022 Cell & Gene Meeting on the Mesa
GlobeNewsWire
05 окт 2022 г. в 16:01
EDEN PRAIRIE, Minn., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that CEO Jeff Ross will present at the 2022 Cell & Gene Meeting on the Mesa. The three day event held this year on October 11-13 features in-person and pre-recorded virtual presentations by leading public and private companies highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and regenerative medicine.
Miromatrix CEO Jeff Ross to Present at the Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event
GlobeNewsWire
26 сент 2022 г. в 16:01
EDEN PRAIRIE, Minn., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced CEO Jeff Ross will present at the Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event. The two-day virtual event held this year on September 28-29, will focus the first day on solid organ transplant (SOT), in particular, kidney transplants, and the second day on the unmet need and innovations in hematopoietic stem cell transplant (HSCT).